These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 7600120)

  • 1. Effects of recombinant hirudin (r-hirudin, HBW 023) on coagulation and platelet activation in vivo. Comparison with unfractionated heparin and a low-molecular-weight heparin preparation (fragmin).
    Eichinger S; Wolzt M; Schneider B; Nieszpaur-Los M; Heinrichs H; Lechner K; Eichler HG; Kyrle PA
    Arterioscler Thromb Vasc Biol; 1995 Jul; 15(7):886-92. PubMed ID: 7600120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
    Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.
    Sarich TC; Wolzt M; Eriksson UG; Mattsson C; Schmidt A; Elg S; Andersson M; Wollbratt M; Fager G; Gustafsson D
    J Am Coll Cardiol; 2003 Feb; 41(4):557-64. PubMed ID: 12598065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
    Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
    Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin blunts endotoxin-induced coagulation activation.
    Pernerstorfer T; Hollenstein U; Hansen J; Knechtelsdorfer M; Stohlawetz P; Graninger W; Eichler HG; Speiser W; Jilma B
    Circulation; 1999 Dec 21-28; 100(25):2485-90. PubMed ID: 10604885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo.
    Weltermann A; Wolzt M; Petersmann K; Czerni C; Graselli U; Lechner K; Kyrle PA
    Arterioscler Thromb Vasc Biol; 1999 Jul; 19(7):1757-60. PubMed ID: 10397695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulation inhibition capacities of low-molecular mass and unfractionated heparin, as determined by thrombin generation.
    Elgue G; Sanchez J; Egberg N; Olsson P
    Thromb Res; 1994 Sep; 75(5):539-49. PubMed ID: 7992254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enoxaparin, a low-molecular-weight heparin suppresses prothrombin activation more effectively than unfractionated heparin in patients treated for venous thromboembolism.
    Grosset AB; Spiro TE; Beynon J; Rodgers GM
    Thromb Res; 1997 Jun; 86(5):349-54. PubMed ID: 9211625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis.
    Bossavy JP; Sakariassen KS; Rübsamen K; Thalamas C; Boneu B; Cadroy Y
    Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1348-53. PubMed ID: 10323789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombin-Hirudin complex formation, thrombin-antithrombin III complex formation, and thrombin generation after intrinsic activation of plasma.
    Gallistl S; Muntean W
    Thromb Haemost; 1994 Sep; 72(3):387-92. PubMed ID: 7855789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. r-Hirudin inhibits platelet-dependent thrombosis during cardiopulmonary bypass in baboons.
    van Wyk V; Neethling WM; Badenhorst PN; Kotzé HF
    J Cardiovasc Surg (Torino); 1998 Oct; 39(5):633-9. PubMed ID: 9833724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombin formation and effect of unfractionated heparin during pediatric cardiac catheterization.
    Chen D; Långström S; Petäjä J; Heikinheimo M; Pihkala J
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1174-9. PubMed ID: 22915548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The course of disseminated intravascular coagulation is predicted by changes in thrombin-antithrombin III complex levels--is there any difference between treatment with standard heparin or low-molecular-weight heparin?
    Asakura H; Jokaji H; Saito M; Uotani C; Kumabashiri I; Morishita E; Yamazaki M; Matsuda T
    Blood Coagul Fibrinolysis; 1991 Oct; 2(5):623-7. PubMed ID: 1664251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets.
    Sagedal S; Hartmann A; Sundstrøm K; Bjørnsen S; Brosstad F
    Nephrol Dial Transplant; 2001 May; 16(5):987-93. PubMed ID: 11328905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory assays for the evaluation of recombinant hirudin.
    Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
    Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of synthetic pentasaccharide, low-molecular-weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma.
    Gerotziafas GT; Bara L; Bloch MF; Makris PE; Samama MM
    Blood Coagul Fibrinolysis; 1998 Oct; 9(7):571-80. PubMed ID: 9863704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.
    Rao AK; Sun L; Chesebro JH; Fuster V; Harrington RA; Schwartz D; Gallo P; Matos D; Topol EJ
    Circulation; 1996 Nov; 94(10):2389-95. PubMed ID: 8921778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro studies on thrombin generation in citrated, r-hirudinized and heparinized whole blood.
    Kaiser B; Fareed J; Walenga JM; Hoppensteadt D; Markwardt F
    Thromb Res; 1991 Dec; 64(5):589-96. PubMed ID: 1808763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.